Associate Professor & Hepatologist at University of Leeds. Interested in outcomes in liver disease. President elect BASL. Views my own.
Leeds, England
Joined November 2012
- Tweets2.2K
- Following1.2K
- Followers2.3K
- Likes8.1K
Pinned Tweet
The placebo response in #NASH, simply explained
@AGA_CGH tinyurl.com/dkvfxhd4
1⃣ Sampling variability explains the majority of the placebo response
2⃣Fibrosis progression in trials slower than in observational studies
3⃣Is liver biopsy a reliable endpoint? #LiverTwitter
Ian Rowe retweeted
Great start to the year! Thank you to our team at St. James for randomising our first PROMISE participant of the year @IanARowe @rebwillow @DebbieShawcros1 #FMT #Clinicaltrials #Clinicalresearch #PROMISEtrial
Conference abstracts serve a purpose for students and trainees
There is the experience of doing the work
It gives people a chance to be part of the community, to meet experts and future collaborators and colleagues
@basl_events the poster round is the BEST part of the meeting
In defense of conference abstracts
I went to @DDWMeeting in 2009 as a medical student. I worked HARD to produce an abstract. I learned a TON. I was in AWE of all the talks from people whose papers I read. An EXPERT came by my poster and destroyed it. I will NEVER forget
1/
Great fun think about this for @JHepatology
Need to think about whole patient benefit of treatment for individuals with #MASLD and other metabolic multi morbidity
Many patients with MASLD will receive effective treatment before hepatology involvement
Brilliant editorial by @IanARowe: A “typical" (T2DM, HTA, BMI 34, DLP) at-risk MASH patient faces ~12% 10yr CV risk but only 1-3% liver-event risk. This gap shows management should prioritise weight loss and metabolic control before liver-directed therapy.journal-of-hepatology.eu/art…
Privileged to be part of this wide-ranging discussion #EASLStudio at the #EASLCongress
We explored lots of the important issues around screening for liver disease and why it is critical that we build the evidence base to support it
Free to watch back, it's worth the time!
Watch #EASLStudio to find out how are projects like @LIVERAiM are aiming to change the game when it comes to diagnosing #LiverDiseases early
📅Starting at 16:15 CEST
📍Onsite: Hepatology Arena
💻Online: : easl.eu/studio-at-easl-congr…
@EASLnews @aelsharkawy75 @majathiele @IanARowe
@Yujun__Wong @apichatka @BavenoCoop
#EASLCongress
Really looking forward to these conversations, lots of unresolved issues and questions to be answered
Come along and hear what we still need to understand
#EASLCongress
Tune in to this episode of #EASLStudio as the faculty explores the pros and cons of early screening.
📅Thursday, 8 May at 16:15 CEST
📍Onsite: Hepatology Arena
💻Online: : easl.eu/studio-at-easl-congr…
@EASLNews @aelsharkawy75 @majathiele @IanARowe @LiverAim @Yujun__Wong @apichatka @BavenoCoop
#LiverX #EASLCongress
Ian Rowe retweeted
#EASLStudio live from #EASLcongress will be back tomorrow morning with another great lineup! 🤩
As usual you can tune in online 💻easl.eu/studio-at-easl-congr…
or attend on site in the Hepatology Arena.
@EASLNews
#LiverX
We've made it to Amsterdam, fresh and ready for @EASLedu #EASLCongress
Happy to support raising awareness of liver health and disease
@LiverTrust @LeedsHospitals
Looking forward to catching up with friends and colleagues @EASLedu
But first, cycling for liver health and sustainability. Stage 1 complete, next stage Rotterdam to Amsterdam tomorrow!
#EASLCongress
This was very much a team effort!
The heavy lifting was done by @KatrinaPekarska from @LIMR_PGstudents and @drrichardparker
Much value in reproducing work in this context, highlighting the role of #alcohol in driving liver disease
@LeedsHospitals
Reproducibility is always difficult in medicine 🎯
New data confirming our result on the synergistic effect between CMRF and alcohol consumption in SLD ✅
journal-of-hepatology.eu/art…
Fantastic work lead by @leeds_liver @IanARowe
@rabataller @DrJavierCrespo @DrJLCalleja
Ian Rowe retweeted
🔥 Off the press
New data on Steatotic Liver Disease @JCEH_Hepatology
Highlighting the effects of 🍷on outcomes
Check out
👇🏽 jcehepatology.com/article/S0…
@drnipunverma @juanpabloarab @DrLoomba @ajay_duseja @AnandVKulkarni2 @docMPK @DrAshish_Kumar @LiverFellow @ebtapper @MajaThiele
Important data in #MASH but probably not the game changer some think
75% of patients had a potential indication for SEMA, BMI>30 or T2DM
GLP1RA is a foundational treatment for patients with metabolic multimorbidity
If initiated for those reasons, MASH indication not needed
Semaglutide improved inflammation and fibrosis in people with MASH / NASH
1. Generalizable gem: 10% body weight loss is the target to reverse fibrosis
2. Monkey on the back: inflammation endpoints with huge placebo effect
nejm.org/doi/full/10.1056/NE…
So much to say on #ESSENCE
Placebo response = sampling variability, see cghjournal.org/article/S1542…
Also, improvements in steatosis at least are mediated through weight loss, see
jhep-reports.eu/article/S258…
@ebtapper
This should be a fun discussion - there is no perfect scheme for allocation of livers...
Lots of issues to talk about!
@BASLedu @NHSBT_Stats @LiverTrust
Following on from our great @BLTGedu webinar on PTLD, April 3rd 18.30 we have our next webinar on the challenges around organ allocation - case from Birmingham followed by a talk from @IanARowe - sign up below!
@BASLedu @BTPTSociety @BSGTrainees
basl.org.uk/index.cfm/events…
Interesting morning promoting organ transplantation!
I will never tire of seeing the impact transplant has on recipients and their families and am privileged to be able to play a small part in the process
@LeedsHospitals @NHSBT @leeds_liver
Ian Rowe retweeted
You are invited to play HepMadness
Brought to you by @LiverFellow
Fill out a bracket: tourneytopia.com/aasld/hepma…
Pick your winners amongst the hottest topics in all of liverland and, maybe, win a prize
Inspired by work published in @LTxJournal and @HepCommJournal
Ian Rowe retweeted
Congratulations @IanARowe for this excellent methodological review of HCC risk models, which I will use for my next HCC risk model 😉
& reach out to you and Hamish Innes for some validation data!
See next for thoughts on using Competing Risk models
🟪NEW Article in press❕
Hepatocellular Carcinoma risk scores for non-viral liver disease: a systematic review and meta-analysis
🔓#OpenAccess at 👉 jhep-reports.eu/article/S258…
#LiverTwitter
#HCC
Ian Rowe retweeted
Had to be done and we are proud @HepCommJournal brings the first concordance of MASLD and NAFLD study in pediatrics
journals.lww.com/hepcomm/ful…
@IanARowe
Ian Rowe retweeted
Fantastic @basl_events annual meeting 🙌🏼
BASL end of life SIG meeting upcoming:
7th November 2024
Birmingham
Multiprofessional
Free attendance
Hybrid
Contact [email protected]
@REDUCe2study @EVOLVE_EOLC @CathyJBeresford #palliativehepatology #ESLD #EOLC
Programme 👇🏼
Ian Rowe retweeted
Could you help us prevent relapse to alcohol for patients with advanced liver disease?
If you work in this area or are a patient or caregiver, please consider sharing your views by completing our short survey.
thiscovery.org/preventing-re…
Hey #livertwitter
Talking this week at #BASL2024 - research studies round up
What are your top 3 research studies in the last 12 months?
What has changed your practice?
@EASLedu @AASLDtweets @BASLedu